Your browser doesn't support javascript.
loading
The clinical and genetic spectrum of autosomal-recessive TOR1A-related disorders.
Saffari, Afshin; Lau, Tracy; Tajsharghi, Homa; Karimiani, Ehsan Ghayoor; Kariminejad, Ariana; Efthymiou, Stephanie; Zifarelli, Giovanni; Sultan, Tipu; Toosi, Mehran Beiraghi; Sedighzadeh, Sahar; Siu, Victoria Mok; Ortigoza-Escobar, Juan Darío; AlShamsi, Aisha M; Ibrahim, Shahnaz; Al-Sannaa, Nouriya Abbas; Al-Hertani, Walla; Sandra, Whalen; Tarnopolsky, Mark; Alavi, Shahryar; Li, Chumei; Day-Salvatore, Debra-Lynn; Martínez-González, Maria Jesús; Levandoski, Kristin M; Bedoukian, Emma; Madan-Khetarpal, Suneeta; Idleburg, Michaela J; Menezes, Minal Juliet; Siddharth, Aishwarya; Platzer, Konrad; Oppermann, Henry; Smitka, Martin; Collins, Felicity; Lek, Monkol; Shahrooei, Mohmmad; Ghavideldarestani, Maryam; Herman, Isabella; Rendu, John; Faure, Julien; Baker, Janice; Bhambhani, Vikas; Calderwood, Laurel; Akhondian, Javad; Imannezhad, Shima; Mirzadeh, Hanieh Sadat; Hashemi, Narges; Doosti, Mohammad; Safi, Mojtaba; Ahangari, Najmeh; Torbati, Paria Najarzadeh; Abedini, Soheila.
Afiliação
  • Saffari A; Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
  • Lau T; Division of Child Neurology and Inherited Metabolic Diseases, Heidelberg University Hospital, Heidelberg, Germany.
  • Tajsharghi H; Department of Neuromuscular Diseases, Queen Square Institute of Neurology, University College London, London, UK.
  • Karimiani EG; School of Health Sciences, Division of Biomedicine, University of Skovde, Skovde, Sweden.
  • Kariminejad A; Molecular and Clinical Sciences Institute, St. George's, University of London, Cranmer Terrace, London, UK.
  • Efthymiou S; Department of Medical Genetics, Next Generation Genetic Polyclinic, Mashhad, Iran.
  • Zifarelli G; Kariminejad-Najmabadi Pathology & Genetics Center, Tehran, Iran.
  • Sultan T; Department of Neuromuscular Diseases, Queen Square Institute of Neurology, University College London, London, UK.
  • Toosi MB; CENTOGENE GmbH, Am Strande 7, 18055 Rostock, Germany.
  • Sedighzadeh S; Department of Neuromuscular Diseases, Queen Square Institute of Neurology, University College London, London, UK.
  • Siu VM; Department of Pediatrics, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Ortigoza-Escobar JD; Neuroscience Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
  • AlShamsi AM; Department of Biological Sciences, Faculty of Science, Shahid Chamran University of Ahvaz, Ahvaz, Iran.
  • Ibrahim S; KaryoGen, Isfahan, Iran.
  • Al-Sannaa NA; Division of Medical Genetics, Department of Pediatrics, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.
  • Al-Hertani W; Movement Disorders Unit, Pediatric Neurology Department, Institut de Recerca, Hospital Sant Joan de Déu Barcelona, Barcelona, Spain.
  • Sandra W; Genetic Division, Pediatrics Department, Tawam Hospital, Al Ain, UAE.
  • Tarnopolsky M; Department of pediatrics and child Health, Aga Khan University, Karachi, Pakistan.
  • Alavi S; Pediatric Services, John Hopkins Aramco Health Care, Dhahran, Saudi Arabia.
  • Li C; Harvard Medical School, Boston Children's Hospital, Department of Pediatrics, Division of Genetics and Genomics, Boston, MA, USA.
  • Day-Salvatore DL; APHP UF de Génétique Clinique, Centre de Référence des Anomalies du Développement et Syndromes Malformatifs, APHP, Hôpital Armand Trousseau, ERN ITHACA, Sorbonne Université, Paris, France.
  • Martínez-González MJ; Department of Pediatrics (MT - Neuromuscular and Neurometabolics, CL - Medical Genetics), McMaster Children's Hospital, Hamilton, Ontario, Canada.
  • Levandoski KM; Department of Neuromuscular Diseases, Queen Square Institute of Neurology, University College London, London, UK.
  • Bedoukian E; Department of Pediatrics (MT - Neuromuscular and Neurometabolics, CL - Medical Genetics), McMaster Children's Hospital, Hamilton, Ontario, Canada.
  • Madan-Khetarpal S; The Department of Medical Genetics and Genomic Medicine at Saint Peter's University Hospital, New Brunswick, NJ, USA.
  • Idleburg MJ; Pediatric Neurology Unit, Cruces University Hospital, Barakaldo, Vizcaya, Spain.
  • Menezes MJ; The Department of Medical Genetics and Genomic Medicine at Saint Peter's University Hospital, New Brunswick, NJ, USA.
  • Siddharth A; Roberts Individualized Medical Genetics Center, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Platzer K; Division of Genetic and Genomic Medicine, Department of Pediatrics, UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Oppermann H; Division of Genetic and Genomic Medicine, Department of Pediatrics, UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Smitka M; Department of Anaesthesia, the Children's Hospital at Westmead, Sydney, NSW, Australia.
  • Collins F; Discipline of Child and Adolescent Health, and Specialty of Genomic Medicine, Sydney Medical School, Sydney University, Sydney, NSW, Australia.
  • Lek M; Harvard Medical School, Boston Children's Hospital, Department of Pediatrics, Division of Genetics and Genomics, Boston, MA, USA.
  • Shahrooei M; Institute of Human Genetics, University of Leipzig Medical Center, Leipzig, Germany.
  • Ghavideldarestani M; Institute of Human Genetics, University of Leipzig Medical Center, Leipzig, Germany.
  • Herman I; Department of Neuropediatrics, Medical Faculty Carl Gustav Carus, Technical University Dresden, Dresden, Germany.
  • Rendu J; Discipline of Child and Adolescent Health, and Specialty of Genomic Medicine, Sydney Medical School, Sydney University, Sydney, NSW, Australia.
  • Faure J; Department of Clinical Genetics, Children's Hospital at Westmead, Sydney, NSW, Australia.
  • Baker J; Department of Genetics, Yale School of Medicine, New Haven, Connecticut, USA.
  • Bhambhani V; Medical Laboratory of Dr. Shahrooei, Tehran, Iran.
  • Calderwood L; Department of Microbiology and Immunology, Clinical and Diagnostic Immunology, KU Leuven, Leuven, Belgium.
  • Akhondian J; Medical Laboratory of Dr. Shahrooei, Tehran, Iran.
  • Imannezhad S; Section of Pediatric Neurology and Developmental Neuroscience, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
  • Mirzadeh HS; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.
  • Hashemi N; Texas Children's Hospital, Houston, TX, USA.
  • Doosti M; Division of Pediatric Neuroscience, Boys Town National Research Hospital, Boys Town, NE, USA.
  • Safi M; Univ. Grenoble Alpes, Inserm, U1216, CHU Grenoble Alpes, Grenoble Institut Neurosciences, Grenoble, France.
  • Ahangari N; Univ. Grenoble Alpes, Inserm, U1216, CHU Grenoble Alpes, Grenoble Institut Neurosciences, Grenoble, France.
  • Torbati PN; Division of Genetics and Genomic Medicine, Children's Hospital and Clinics of Minnesota, Minneapolis, Minnesota, USA.
  • Abedini S; Division of Genetics and Genomic Medicine, Children's Hospital and Clinics of Minnesota, Minneapolis, Minnesota, USA.
Brain ; 146(8): 3273-3288, 2023 08 01.
Article em En | MEDLINE | ID: mdl-36757831
ABSTRACT
In the field of rare diseases, progress in molecular diagnostics led to the recognition that variants linked to autosomal-dominant neurodegenerative diseases of later onset can, in the context of biallelic inheritance, cause devastating neurodevelopmental disorders and infantile or childhood-onset neurodegeneration. TOR1A-associated arthrogryposis multiplex congenita 5 (AMC5) is a rare neurodevelopmental disorder arising from biallelic variants in TOR1A, a gene that in the heterozygous state is associated with torsion dystonia-1 (DYT1 or DYT-TOR1A), an early-onset dystonia with reduced penetrance. While 15 individuals with AMC5-TOR1A have been reported (less than 10 in detail), a systematic investigation of the full disease-associated spectrum has not been conducted. Here, we assess the clinical, radiological and molecular characteristics of 57 individuals from 40 families with biallelic variants in TOR1A. Median age at last follow-up was 3 years (0-24 years). Most individuals presented with severe congenital flexion contractures (95%) and variable developmental delay (79%). Motor symptoms were reported in 79% and included lower limb spasticity and pyramidal signs, as well as gait disturbances. Facial dysmorphism was an integral part of the phenotype, with key features being a broad/full nasal tip, narrowing of the forehead and full cheeks. Analysis of disease-associated manifestations delineated a phenotypic spectrum ranging from normal cognition and mild gait disturbance to congenital arthrogryposis, global developmental delay, intellectual disability, absent speech and inability to walk. In a subset, the presentation was consistent with foetal akinesia deformation sequence with severe intrauterine abnormalities. Survival was 71%, with higher mortality in males. Death occurred at a median age of 1.2 months (1 week-9 years), due to respiratory failure, cardiac arrest or sepsis. Analysis of brain MRI studies identified non-specific neuroimaging features, including a hypoplastic corpus callosum (72%), foci of signal abnormality in the subcortical and periventricular white matter (55%), diffuse white matter volume loss (45%), mega cisterna magna (36%) and arachnoid cysts (27%). The molecular spectrum included 22 distinct variants, defining a mutational hotspot in the C-terminal domain of the Torsin-1A protein. Genotype-phenotype analysis revealed an association of missense variants in the 3-helix bundle domain to an attenuated phenotype, while missense variants near the Walker A/B motif as well as biallelic truncating variants were linked to early death. In summary, this systematic cross-sectional analysis of a large cohort of individuals with biallelic TOR1A variants across a wide age-range delineates the clinical and genetic spectrum of TOR1A-related autosomal-recessive disease and highlights potential predictors for disease severity and survival.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Distúrbios Distônicos / Distonia / Malformações do Sistema Nervoso Tipo de estudo: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Distúrbios Distônicos / Distonia / Malformações do Sistema Nervoso Tipo de estudo: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Ano de publicação: 2023 Tipo de documento: Article